8.77
Prothena Corporation Plc stock is traded at $8.77, with a volume of 1.23M.
It is up +2.45% in the last 24 hours and up +34.30% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$8.56
Open:
$8.63
24h Volume:
1.23M
Relative Volume:
0.80
Market Cap:
$472.09M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-8.77
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+6.30%
1M Performance:
+34.30%
6M Performance:
-43.64%
1Y Performance:
-58.73%
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PRTA
Prothena Corporation Plc
|
8.77 | 459.17M | 217.25M | -50.92M | -100.85M | -1.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
May-27-25 | Downgrade | Jefferies | Buy → Hold |
May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Apr-24-23 | Initiated | SVB Securities | Outperform |
Jan-27-23 | Initiated | Piper Sandler | Overweight |
Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
Jun-08-21 | Reiterated | Oppenheimer | Outperform |
May-26-21 | Initiated | Citigroup | Buy |
Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
Dec-07-20 | Initiated | H.C. Wainwright | Buy |
Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
Apr-05-18 | Reiterated | Barclays | Overweight |
Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
Sep-29-17 | Reiterated | BTIG Research | Buy |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Jul-11-17 | Initiated | Jefferies | Buy |
Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
Apr-12-17 | Initiated | Piper Jaffray | Overweight |
Mar-02-17 | Initiated | Instinet | Buy |
Dec-21-16 | Initiated | SunTrust | Buy |
Nov-03-16 | Initiated | Deutsche Bank | Buy |
Aug-04-16 | Reiterated | Barclays | Overweight |
May-13-16 | Initiated | Barclays | Overweight |
Feb-19-16 | Reiterated | Wedbush | Outperform |
Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Prothena Corporation plc stock outlook for YEARPortfolio Profit Report & High Win Rate Trade Alerts - Newser
Strategies to average down on Prothena Corporation plcJuly 2025 Update & Short-Term High Return Ideas - Newser
Is Prothena Corporation plc still worth holding after the dipWeekly Trend Report & Intraday High Probability Setup Alerts - Newser
How institutional ownership impacts Prothena Corporation plc stockWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Can swing trading help recover from Prothena Corporation plc lossesWeekly Stock Recap & Consistent Growth Equity Picks - Newser
Tick level data insight on Prothena Corporation plc volatilityBuy Signal & Free Weekly Chart Analysis and Trade Guides - Newser
Using data models to predict Prothena Corporation plc stock movement2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Earnings visualization tools for Prothena Corporation plcQuarterly Market Review & Real-Time Stock Price Movement Reports - Newser
Is Prothena Corporation plc trending in predictive chart modelsMarket Risk Analysis & Short-Term High Return Ideas - Newser
Relative strength of Prothena Corporation plc in sector analysisJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Ranking Prothena Corporation plc among high performing stocks via tools2025 Technical Overview & Stock Portfolio Risk Management - Newser
Will a bounce in Prothena Corporation plc offer an exitPortfolio Update Summary & Target Return Focused Stock Picks - Newser
Key resistance and support levels for Prothena Corporation plcPrice Action & Expert Curated Trade Ideas - Newser
Will Prothena Corporation plc see short term momentum2025 Trading Recap & Growth Focused Entry Reports - Newser
Recovery Signals Appearing in Prothena Corporation plc Charts2025 Macro Impact & High Conviction Buy Zone Picks - beatles.ru
Is Prothena Corporation plc Forming a Consolidation Base2025 Historical Comparison & Accurate Buy Signal Alerts - beatles.ru
Prothena Corporation plc Stocks Attracting Dip Buyers2025 Support & Resistance & Accurate Intraday Trade Tips - newsyoung.net
Published on: 2025-08-14 23:29:29 - sundaytimes.kr
Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes By Investing.com - Investing.com Canada
Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes - Investing.com
Can trapped investors hope for a rebound in Prothena Corporation plcFree Investment Strategy With Low Risk - Newser
What MACD signals say about Prothena Corporation plcForecast Model for Intraday Buy Signals - Newser
How to escape a deep drawdown in Prothena Corporation plcFree Low Risk High Return Opportunities - Newser
How to build a dashboard for Prothena Corporation plc stockSummary of Reliable Long-Term Trade Models - Newser
Building trade automation scripts for Prothena Corporation plcBreakout Stock Opportunities with Low Drawdown - Newser
Volume spikes in Prothena Corporation plc stock – what they meanFree Safe Entry Stock Watch Suggestions - Newser
How Prothena Corporation plc stock performs during market volatilityLow Exposure Strategy with Sector Analysis - Newser
Trend Reversal Possible in Prothena Corporation plc Charts IndicateSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Royal Bank Of Canada Cuts Prothena (NASDAQ:PRTA) Price Target to $10.00 - Defense World
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - BioSpace
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful - Investing.com India
Prothena (PRTA) Surges on Novo Nordisk's Phase 3 Plans for ATTR Amyloidosis Drug - GuruFocus
Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk - TipRanks
Prothena Announces that Novo Nordisk Will Advance Coramitug (For - GuruFocus
Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential - Stock Titan
Applying sector rotation models to Prothena Corporation plcFree Swing Trading Entry Point Signals - Newser
Prothena announces that Novo Nordisk will advance Coramitug into phase 3 development - MarketScreener
Prothena stock price target lowered to $10 at RBC on program discontinuation By Investing.com - Investing.com South Africa
Prothena stock price target lowered to $10 at RBC on program discontinuation - Investing.com Nigeria
PRTA: RBC Capital Maintains Rating, Lowers Price Target | PRTA S - GuruFocus
9 Analysts Assess Prothena Corp: What You Need To Know - 富途牛牛
Prothena’s Losses Grow As Revenue Drops And Programs Wind Down - Finimize
RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk - MarketScreener
Prothena Corp (PRTA) Maintains 'Buy' Rating with $18 Target by C - GuruFocus
JMP reiterates Market Outperform rating on Prothena stock ahead of key data - Investing.com Nigeria
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - BioSpace
Prothena Reports Q2 2025 Financial Results and Pipeline Progress - TipRanks
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corporation Plc Stock (PRTA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):